AnaptysBio, Inc. (ANAB)

Market Cap	382.82M
Revenue (ttm)	14.96M
Net Income (ttm)	-147.82M
Shares Out	26.58M
EPS (ttm)	-5.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,145
Open	14.02
Previous Close	13.85
Day's Range	13.87 - 14.46
52-Week Range	13.36 - 32.44
Beta	-0.22
Analysts	Hold
Price Target	29.00 (+101.32%)
Earnings Date	Nov 2, 2023

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases ass...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB

Financial Performance

In 2022, AnaptysBio's revenue was $10.29 million, a decrease of -83.72% compared to the previous year's $63.18 million. Losses were -$128.72 million, 122.7% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for ANAB stock is "Hold." The 12-month stock price forecast is $29.0, which is an increase of 101.32% from the latest price.

Price Target

$29.0

(101.32% upside)

Analyst Consensus: Hold